Literature DB >> 24677377

Morbidities after maxillary swing nasopharyngectomy for recurrent nasopharyngeal carcinoma.

Jimmy Yu Wai Chan1, Raymond King Yin Tsang, William Ignace Wei.   

Abstract

BACKGROUND: The purpose of this study was to investigate the complications after maxillary swing nasopharyngectomy.
METHODS: Salvage nasopharyngectomy was performed for 338 patients during 1990 to 2012. Patient and tumor characteristics, perioperative and intraoperative information, and long-term morbidities were analyzed.
RESULTS: There were significantly more patients with locally advanced tumors (rT3 and rT4) operated during the recent study period (2002-2012). However, the mean operative time and blood loss was significantly lower than in the earlier period (1990-2001). There was no hospital mortality. There was a significant reduction in the postoperative trismus and palatal fistula formation. Patients with locally advanced tumor, particularly those who required adjuvant chemoradiation, had a higher chance of facial numbness, nasal blockage, and swallowing problems after surgery.
CONCLUSION: Salvage nasopharyngectomy via the maxillary swing approach is safe with acceptable long-term morbidities. Prevention of complications associated with surgery, particularly for patients with locally advanced tumors, is crucial to ensure the best outcome of surgery.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  complications; maxillary swing; morbidities; recurrent nasopharyngeal carcinoma; salvage

Mesh:

Year:  2014        PMID: 24677377     DOI: 10.1002/hed.23633

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  9 in total

1.  Surgical salvage of recurrent nasopharyngeal carcinoma.

Authors:  Jimmy Yu Wai Chan
Journal:  Curr Oncol Rep       Date:  2015-03       Impact factor: 5.075

2.  Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway.

Authors:  Songbin Guo; Jinling Zhang; Cairong Wei; Zhiyong Lu; Rulong Cai; Danqi Pan; Hanbin Zhang; Baoxia Liang; Zhenfeng Zhang
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-24       Impact factor: 3.333

Review 3.  Transpalatal Approaches to the Skull Base and Reconstruction: Indications, Technique, and Associated Morbidity.

Authors:  Nyall R London; Jimmy Y W Chan; Ricardo L Carrau
Journal:  Semin Plast Surg       Date:  2020-05-06       Impact factor: 2.314

4.  An Endoscopic Endonasal Nasopharyngectomy with Posterolateral Extension.

Authors:  Lifeng Li; Nyall R London; Daniel M Prevedello; Ricardo L Carrau
Journal:  J Neurol Surg B Skull Base       Date:  2021-09-29

Review 5.  Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic.

Authors:  Michaela Svajdova; Marian Sicak; Pavol Dubinsky; Marek Slavik; Pavel Slampa; Tomas Kazda
Journal:  Cancers (Basel)       Date:  2020-11-25       Impact factor: 6.639

6.  Development of a Comorbidity-Based Nomogram to Predict Survival After Salvage Reirradiation of Locally Recurrent Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era.

Authors:  Run-Da Huang; Zhuang Sun; Xiao-Hui Wang; Yun-Ming Tian; Ying-Lin Peng; Jing-Yun Wang; Wei-Wei Xiao; Chun-Yan Chen; Xiao-Wu Deng; Fei Han
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

7.  Tolfenamic Acid Inhibits the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma: Involvement of p38-Mediated Down-Regulation of Slug.

Authors:  Tatsanachat Jittreetat; Yoo Seob Shin; Hye Sook Hwang; Bok-Soon Lee; Yeon Soo Kim; Phakdee Sannikorn; Chul-Ho Kim
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

8.  Access to the Skull Base - Maxillary Swing Procedure - Long Term Analysis.

Authors:  Gurudayal Singh Kalra; Manojit Midya; Mitesh Bedi
Journal:  Ann Maxillofac Surg       Date:  2018 Jan-Jun

9.  The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.

Authors:  Ling-Long Tang; Yu-Pei Chen; Chuan-Ben Chen; Ming-Yuan Chen; Nian-Yong Chen; Xiao-Zhong Chen; Xiao-Jing Du; Wen-Feng Fang; Mei Feng; Jin Gao; Fei Han; Xia He; Chao-Su Hu; De-Sheng Hu; Guang-Yuan Hu; Hao Jiang; Wei Jiang; Feng Jin; Jin-Yi Lang; Jin-Gao Li; Shao-Jun Lin; Xu Liu; Qiu-Fang Liu; Lin Ma; Hai-Qiang Mai; Ji-Yong Qin; Liang-Fang Shen; Ying Sun; Pei-Guo Wang; Ren-Sheng Wang; Ruo-Zheng Wang; Xiao-Shen Wang; Ying Wang; Hui Wu; Yun-Fei Xia; Shao-Wen Xiao; Kun-Yu Yang; Jun-Lin Yi; Xiao-Dong Zhu; Jun Ma
Journal:  Cancer Commun (Lond)       Date:  2021-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.